AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
Hirokazu Taniguchi(Memorial Sloan Kettering Cancer Center), Seiji Yano(Kanazawa University Hospital)
Cited by 360
Related Papers
Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study
|Cancer Science|2019|375
Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839)
|Human Molecular Genetics|2004|174
Targeted Therapies and Biomarkers in Small Cell Lung Cancer
|Frontiers in Oncology|2020|112
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer
|Nature Communications|2020|112